GRM5 and fragile X syndrome: Non-competitive metabotropic glutamate receptor 5 (mGluR5) antagonists are viewed as having promise against a number of CNS and peripheral diseases, including the treatment of pain, anxiety, gastro-esophageal reflux disease (GERD), Fragile X syndrome, and Parkinson’s disease.